Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Joe Wesley who wrote (1361)	12/4/1997 7:16:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 4676

>>3) 2302 Ulcerative Colitis: My guess is drug will be as good as Crohn's however this is a problem trial because a)FDA will not allow patients who are bleeding in the trial (most patients are bleeding) b) surgery is considered a cure (not in Crohn's) developing proper protocol is a big problem. IMO Isis is moving ahead here.<< Any more info about this? Why wouldn't they allow bleeding patients in the trial? As you say, the serious cases are bleeding. Does that mean that the results will only apply to that class of patients which is not bleeding? Sounds completely off the wall to me.